Drug Profile
DiAo
Latest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator KONRUNS Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 11 Oct 2021 Discontinued - Phase-III for Solid tumours in China (unspecified route) (Konruns Pharmaceutical website, October 2021)